On October 20, 2020 WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs) products for cancer immunotherapy, reported that data regarding MILs as a potential cancer immunotherapy for hematological and solid tumors has been selected for a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting which will take place virtually November 9 – 14, 2020 (Press release, WindMIL Therapeutics, OCT 20, 2020, View Source [SID1234568826]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentation are as follows:

Title: Marrow-infiltrating Lymphocytes (MILs): A Novel Adoptive Immunotherapy for Hematological and Solid Tumors
Abstract ID: 14151
Presenter: Eric Lutz, PhD, Director of Research, WindMIL Therapeutics

A copy of the abstract can be viewed online through the SITC (Free SITC Whitepaper) website. The presentation will be available in the Virtual Poster Hall from November 9 – 14, 2020.